CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it has proven a major foundational hypothesis
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that its ligand conjugated lipid nanoparticle (“LNP”) successfully targeted cancer cells and avoided non-cancerous cells
CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to include liver cancers, specifically rare stem cell-like forms of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Patients with these stem cell-like tumors have a significantly worse survival than patients with more traditional liver tumors
CancerVax, Inc., the developer of a breakthrough universal cancer treatment (UCT) platform designed to use the body’s immune system to treat cancer, today announced the successful creation of its nanoparticle that can target specific cells that are potentially cancerous